Literature DB >> 20035028

Soluble epoxide hydrolase inhibition modulates vascular remodeling.

A N Simpkins1, R D Rudic, S Roy, H J Tsai, B D Hammock, J D Imig.   

Abstract

The soluble epoxide hydrolase enzyme (SEH) and vascular remodeling are associated with cardiovascular disease. Although inhibition of SEH prevents smooth muscle cell proliferation in vitro, the effects of SEH inhibition on vascular remodeling in vivo and mechanisms of these effects remain unclear. Herein we determined the effects of SEH antagonism in an endothelium intact model of vascular remodeling induced by flow reduction and an endothelium denuded model of vascular injury. We demonstrated that chronic treatment of spontaneously hypertensive stroke-prone rats with 12-(3-adamantan-1-yl-ureido) dodecanoic acid, an inhibitor of SEH, improved the increment of inward remodeling induced by common carotid ligation to a level that was comparable with normotensive Wistar Kyoto rats. Similarly, mice with deletion of the gene responsible for the production of the SEH enzyme (Ephx2(-/-)) demonstrated enhanced inward vascular remodeling induced by carotid ligation. However, the hyperplastic response induced by vascular injury that denudes the endothelium was unabated by SEH inhibition or Ephx2 gene deletion. These results suggest that SEH inhibition or Ephx2 gene deletion antagonizes neointimal formation in vivo by mechanisms that are endothelium dependent. Thus SEH inhibition may have therapeutic potential for flow-induced remodeling and neointimal formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20035028      PMCID: PMC2838550          DOI: 10.1152/ajpheart.00543.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  51 in total

1.  Atherosclerosis regression, vascular remodeling, and plaque stabilization.

Authors:  Lloyd W Klein
Journal:  J Am Coll Cardiol       Date:  2006-11-09       Impact factor: 24.094

Review 2.  Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical.

Authors:  Christophe Morisseau; Bruce D Hammock
Journal:  Pest Manag Sci       Date:  2008-06       Impact factor: 4.845

3.  Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population.

Authors:  Laxi Zhang; Hu Ding; Jiangtao Yan; Rutai Hui; Wei Wang; Grace E Kissling; Darryl C Zeldin; Dao Wen Wang
Journal:  Pharmacogenet Genomics       Date:  2008-01       Impact factor: 2.089

4.  Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model.

Authors:  Arzu Ulu; Benjamin B Davis; Hsing-Ju Tsai; In-Hae Kim; Christophe Morisseau; Bora Inceoglu; Oliver Fiehn; Bruce D Hammock; Robert H Weiss
Journal:  J Cardiovasc Pharmacol       Date:  2008-10       Impact factor: 3.105

5.  Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.

Authors:  Marc Revermann; Eduardo Barbosa-Sicard; Eva Dony; Ralph T Schermuly; Christophe Morisseau; Gerd Geisslinger; Ingrid Fleming; Bruce D Hammock; Ralf P Brandes
Journal:  J Hypertens       Date:  2009-02       Impact factor: 4.844

6.  Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension.

Authors:  Jing Li; Mairead A Carroll; Praveen N Chander; John R Falck; Bhavani Sangras; Charles T Stier
Journal:  Front Biosci       Date:  2008-05-01

7.  Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection.

Authors:  Alexis N Simpkins; R Daniel Rudic; Derek A Schreihofer; Sid Roy; Marlina Manhiani; Hsing-Ju Tsai; Bruce D Hammock; John D Imig
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

8.  Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Authors:  Sung Hee Hwang; Hsing-Ju Tsai; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock
Journal:  J Med Chem       Date:  2007-07-06       Impact factor: 7.446

9.  Soluble epoxide hydrolase: a novel therapeutic target in stroke.

Authors:  Wenri Zhang; Ines P Koerner; Ruediger Noppens; Marjorie Grafe; Hsing-Ju Tsai; Christophe Morisseau; Ayala Luria; Bruce D Hammock; John R Falck; Nabil J Alkayed
Journal:  J Cereb Blood Flow Metab       Date:  2007-04-18       Impact factor: 6.200

10.  Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.

Authors:  Mandi J Corenblum; Vance E Wise; Katrin Georgi; Bruce D Hammock; Peter A Doris; Myriam Fornage
Journal:  Hypertension       Date:  2007-12-17       Impact factor: 10.190

View more
  20 in total

Review 1.  Targeting epoxides for organ damage in hypertension.

Authors:  John D Imig
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

2.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

Review 3.  Role of microglia under cardiac and cerebral ischemia/reperfusion (I/R) injury.

Authors:  Poomarin Surinkaew; Passakorn Sawaddiruk; Nattayaporn Apaijai; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Metab Brain Dis       Date:  2018-04-14       Impact factor: 3.584

Review 4.  Cytochrome P450 eicosanoids and cerebral vascular function.

Authors:  John D Imig; Alexis N Simpkins; Marija Renic; David R Harder
Journal:  Expert Rev Mol Med       Date:  2011-03-01       Impact factor: 5.600

5.  Proteomics and bioinformatics analysis of mouse hypothalamic neurogenesis with or without EPHX2 gene deletion.

Authors:  Lijun Zhong; Juntuo Zhou; Dawei Wang; Xiajuan Zou; Yaxin Lou; Dan Liu; Bin Yang; Yi Zhu; Xiaoxia Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 6.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

7.  Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.

Authors:  Marc Revermann; Manuel Schloss; Eduardo Barbosa-Sicard; Anja Mieth; Stefan Liebner; Christophe Morisseau; Gerd Geisslinger; Ralph T Schermuly; Ingrid Fleming; Bruce D Hammock; Ralf P Brandes
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-03-11       Impact factor: 8.311

8.  Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.

Authors:  Yingmei Liu; Heather K Webb; Hisayo Fukushima; Janine Micheli; Svetlana Markova; Jean L Olson; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2012-03-13       Impact factor: 4.030

Review 9.  Vascular pharmacology of epoxyeicosatrienoic acids.

Authors:  Sandra L Pfister; Kathryn M Gauthier; William B Campbell
Journal:  Adv Pharmacol       Date:  2010

Review 10.  Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.

Authors:  J D Imig
Journal:  Adv Pharmacol       Date:  2016-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.